-
Iptacopan
API’s Name CAS No. US DMF EU DMF Patent Expiry Date( U.S) Iptacopan hydrochloride 1646321-63-2 2027.Q1 Jul.14,2034 Iptacopan hydrochloride monohydrate 2447007-60-3 2027.Q1 May,2041 [Indication]
- Paroxysmal nocturnal hemoglobinuria (PNH)：For the treatment of PNH in adult patients.
- C3 glomerulopathy (C3G)：For the treatment of C3G in adult patients to reduce proteinuria.
- Immunoglobulin A nephropathy (IgAN)：For the treatment of primary IgAN in adult patients with rapid progression risk to reduce proteinuria levels.
-
Suzetrigine (CAS: 2649467-58-1)
API’s Name US DMF EU DMF Patent Expiry Date(The U.S) Suzetrigine Dec, 2026 Dec.4,2040 [Product]
Provide the API as well as the SDD (Spray Dried Dispersion).
[Indication]
For the management of acute pain of moderate to severe intensity in adults.
-
Orforglipron (CAS: 2212020-52-3)
API’s Name CAS No. US DMF EU DMF Patent Expiry Date(US) Orforglipron 2212020-52-3 Nov, 2026 Sep.26,2037 [Product]
Provide the API as well as the SDD (Spray Dried Dispersion)
[Indication]
- Type 2 diabetes mellitus:To improve glycemic control in adults with type 2 diabetes mellitus.
- For clinical research, now it can be used for Chronic weight management in adults.
-
Osimertinib (CAS: 1421373-66-1)
API’s Name CAS No. US DMF EUDMF Patent Expiry Date( US) Osimertinib Mesylate 1421373-66-1 Nov,2026 Aug.8,2032 [Indication]
- For the adjuvant treatment of patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R mutation.
- For the first-line treatment of adults with metastatic or locally advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation.
- For the treatment of adults with locally advanced or metastatic NSCLC who have disease progression after treatment with EGFR-TKI and whose tumors are positive for EGFR T790M mutation.
-
Alectinib (CAS: 1256589-74-8)
API’s Name CAS No. US DMF EU DMF Patent Expiry Date( US) Alectinib Hydrochloride 1256589-74-8 Dec,2026 Jun. 9,2030 [Indication]
- For the adjuvant treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) after surgery.
- For the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC).
-
Zanubrutinib (CAS: 1691249-45-2)
API’s Name CAS No. US DMF EU DMF Patent Expiry Date(US) Zanubrutinib 1691249-45-2 2027 Apr.2034 [Product]
Provide the API.
[Indication]
MCL：Zanubrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy.
CLL/SLL：Zanubrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
WM：Zanubrutinib is indicated for the treatment of adult patients with relapsed or refractory Waldenström’s macroglobulinemia (WM).
FL：Zanubrutinib in combination with obinutuzumab is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
-
Dabrafenib (CAS: 1195765-45-7)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Dabrafenib Melanoma Novartis（GSK R&D） Jul.20, 2030 -
Aprocitentan (CAS: 1103522-45-7)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Aprocitentan hypertension Idorsia Pharmaceuticals Deutschland GmbH Sep. 21.2034 -
Etrasimod (CAS: 1206123-37-6)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Etrasimod Ulceratuve Colitis(UC) Arena(Pfizer) Mar.05,2030 -
Tirzepatide (CAS: 2023788-19-2)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Tirzepatide Type 2 diabetes, lose weight Eli Lilly Jan.05,2036 -
Semaglutide (CAS: 910463-68-2)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Semaglutide Type2 diabetes,lose weight Novo Nordisk Dec.05,2031 -
Oteseconazole (CAS: 1340593-59-0)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Oteseconazole Reduce the incidence rate ofrecurrent vulvovaginal candidiasis MycoviaPharmaceuticals Apr.22,2031